SCHEMBL2865355

SCHEMBL2865355

Nc1c2c(=O)[nH]c3cc(OCCCN4CCOCC4)ccc3c2nn1-c1ccc(Oc2ccccc2)c(O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.43
PDGFRB P09619 1/20 0.43
KDR P35968 1/20 0.43
CHEK1 O14757 1/20 0.40
WEE1 P30291 1/20 0.40
CSF1R P07333 1/20 0.40
RAF1 P04049 1/20 0.39
MAP2K1 Q02750 1/20 0.39
EPHX2 P34913 2/20 0.39
FGFR2 P21802 1/20 0.39
FGFR3 P22607 1/20 0.39
SRC P12931 1/20 0.38
JAK2 O60674 1/20 0.38
KDM4E B2RXH2 1/20 0.38
BTK Q06187 1/20 0.37
MET P08581 1/20 0.37
MAOA P21397 1/20 0.37
MIF P14174 2/20 0.37
APP P05067 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857971 0.91 FGFR1 (0.48) FGFR1PDGFRBKDRCSF1RRAF1
SCHEMBL2870417 0.91 PDGFRB (0.43) FGFR1PDGFRBKDRCHEK1CSF1R
SCHEMBL2865177 0.87 FGFR1 (0.45) FGFR1PDGFRBKDRFGFR2FGFR3
SCHEMBL2864303 0.85 FGFR1 (0.48) FGFR1PDGFRBKDRCSF1RRAF1
SCHEMBL2866809 0.85 MCHR1 (0.51) FGFR1PDGFRBKDREPHX2SRC
SCHEMBL2861337 0.84 KDM4E (0.50) FGFR1PDGFRBKDRFGFR2FGFR3
SCHEMBL2866686 0.83 CSF1R (0.45) FGFR1PDGFRBKDRCSF1RRAF1
SCHEMBL2868613 0.82 FGFR1 (0.49) FGFR1PDGFRBKDRFGFR2FGFR3
SCHEMBL2861085 0.82 MAOA (0.42) FGFR1PDGFRBKDRCSF1RRAF1
SCHEMBL2860241 0.81 MAP2K1 (0.48) KDRCHEK1CSF1RRAF1MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 FGFR1 201/4885PDGFRB 375/4885KDR 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.